Epidemiological Evidence for Inflammation in Cardiovascular Disease

Introduction

Recent evidence from a wide variety of sources implicates inflammation in the process of atherosclerosis and, ultimately, clinical cardiovascular disease. As summarized recently by Ross,² the biochemical and cell biological evidence clearly supports the position that inflammation is involved in all stages of atherosclerotic development including, but not limited to, oxidative damage,^3,4 cell proliferation, and plaque development and destabilization.⁵ Coagulation, thrombosis, and fibrinolysis are also strongly associated with inflammation, as studies of sepsis⁶ and post-trauma acute phase reaction⁷ have demonstrated.

These relationships are complex. Inflammatory responses are mediated through the cytokine pathway, at least initially, with the major proinflammatory cytokines being interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α). As an example, the generation of proinflammatory cytokines in the setting of sepsis is a powerful procoagulant,⁸ and several coagulation factors, such as fibrinogen and factor VIII, have been known to be acute phase reactants for some time.⁹ Recent studies with purified cytokines support these findings.¹⁰ However, coagulation and fibrinolysis themselves are inflammatory. The production of fibrin degradation products, as the end result of coagulation and fibrinolysis, causes the systemic elaboration of IL-6 (and the up-regulation of liver proteins, such as coagulation factors), which is, most likely, the mechanism by which the body counters consumption of factors.¹¹ We have, therefore, a circular mechanism: inflammation begets coagulation which begets more inflammation. What keeps this process in check? At this point it is uncertain, but it seems reasonable to speculate that on the one hand the elaboration of anti-inflammatory cytokines, e.g., IL-10, play a major role in the inflammatory pathway,¹² while on the other, the factors that down-regulate coagulation, such as activated protein C (APC), at least partly control the coagulation side.¹³

Inflammation appears to be associated with atherothrombotic disease throughout the natural history of this process, from the early stages of fatty streak development, to the rupture of complex plaque with resultant coronary (or peripheral) artery occlusion. Smith et al and Kaplan and colleagues have shown that by-products of coagulation are present in atherosclerotic plaque, including fatty streaks,^14-16 and we have recently shown that increasing IL-6 levels by weekly injection results in a several-fold increase in fatty lesion size in a murine model of early atherosclerosis.¹⁷ As discussed below, abundant evidence links inflammation with atherothrombotic disease in middle-aged populations, using markers ranging from IL-6 itself, to fibrinogen, C-reactive protein (CRP), albumin, and other acute phase proteins. These markers predict events over long periods, again supporting the position that inflammation is associated with all phases of atherothrombotic disease.

Finally, in the elderly, where coronary atherosclerosis is common, inflammation markers are still predictive, but may be more closely linked in time to the events. We believe this is due to the association being driven by the thrombotic component, since atherosclerotic development has often reached an advanced stage. These associations reflect the “proximate pathophysiology” associated with advanced plaque becoming unstable. We believe that the timeframe involved is on the order of 6 to 18 months. We hypothesize that this is different from the “vulnerable plaque” described by Fuster,¹⁸ Davies,¹⁹ and others, since it concerns the exposure of proinflammatory and procoagulant components in older individuals, most likely from complex, advanced plaque, not the lipid-laden, thin-capped plaque of young middle-aged individuals.

• References

• 1 Nieto F. Infections and atherosclerosis: new clues from an old hypothesis?. Am J Epidemiol. 1998; 148: 937-948.
• 2 Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-126.
• 3 Berliner J, Navab M, Fogelman A, Frank J, Demer L, Edwards P, Watson A, Lusis A. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
• 4 Ross R. Inflammation, growth regulatory molecules and atherosclerosis. J. Cellular Biochem. 1992; Supplement 16A: 1-30.
• 5 Buja L, Willerson J. Role of inflammation in coronary plaque disruption. Circulation 1994; 89: 503-5.
• 6 Levi M, ten Cate H, van der Poll T, van Deventer J. Pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270: 975-979.
• 7 Kluft C, Verheijen J, Jie A, Rijken D, Preston F, Sue-Ling H, Jespersen J, Aasen A. The post-operative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast actimg inhibitor of tissue-type plasminogen activator after trauma. Scand. J. Clin. Lab. Invest. 1985; 45: 605-610.
• 8 van Deventer S, Buller H, ten Cate J, Aardern L, Hack j, Sturk A. Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-2526.
• 9 Downton S, Colten H. Acute phase reactants in inflammation and infection. Semin. Hematol. 1988; 25: 84-94.
• 10 Mestries J, Kruithof E, Gascon M, Herodin F, Agay D, Ythier A. In vivo modulation of coagulation and fibrinolysis by recombinant glycosylated human interleukin-6 in baboons. Eur. Cytokine Netw. 1994; 5: 275-81.
• 11 Ritchie D, Levy B, Adams M, Fuller G. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc. Natl. Acad. Sci. USA. 1982; 79: 1530-1534.
• 12 Aggawal B, Puri R. eds. Human cytokines: their role in disease and therapy. Cambridge, MA: Blackwell Science; 1995
• 13 Esmon C, Taylor F, Snow T. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb. Haemostas. 1991; 66: 160-165.
• 14 Bini A, Fenoglio J, Mesa-Tejada R, Kudryk B, Kaplan K. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis: use of monoclonal antibodies. Arteriosclerosis. 1989; 9: 109-121.
• 15 Smith E, Keen G, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arterisclerosis. 1990; 10: 263-275.
• 16 Smith E. Fibrinogen, Fibrin, fibrin degredation products in relation to atherosclerosis. Clinics in Haematology. 1986; 15: 355-370.
• 17 Huber S, Sakkinen P, Rincon M, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol.. In press 1999
• 18 Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am. J. Cardiol. 1995; 76: 24C-33C.
• 19 Davies M. The composition of coronary-artery plaques. N Engl J Med. 1997; 336: 1312-1314.
• 20 Rokitansky C. A Manual of Pathological Anatomy. Philadelphia: Blanchard and Lee; 1855
• 21 Duguid J. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J. Pathol. Bac. 1946; 58: 207-212.
• 22 DeWood M, Spores J, Notske R, Mouser L, Burroughs R, Goldens M, Lang H. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Eng. J. Med. 1980; 303: 897-902.
• 23 Meade T, Brozovic M, Chakrabarti R, Haines A, Imeson J, Mellows S, Miller G, North W, Stirling Y, Thompson S. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537.
• 24 Stone M, Thorp J. Plasma fibrinogen - a major coronary risk factor. J. R. Coll. Gen. Pract. 1985; 35: 565-569.
• 25 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N. Eng. J. Med. 1984; 311: 501-505.
• 26 Yarnell J, Sweetnam P, Elwood P, Eastham R, Gilmour R, O’Brien J, Etherington M. Haemostatic factors and ischaemic heart disease: the Caerphilly study. Br. Heart J. 1985; 53: 483-487.
• 27 Kannel W, Wolf P, Castelli W, D’Agostino R. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA 1987; 258: 1183-1186.
• 28 Folsom A, Wu K, Rosamond W, Sharrett A, Chambless L. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96: 1102-1108.
• 29 Thompson S, Kienast J, Pyke S, Haverkate F, van de Loo J. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N. Engl. J. Med. 1995; 332: 635-641.
• 30 Becker R, Cannon C, Bovill E, Tracy R, Thompson B, Knatterud G, Randall A, Braunwald E. for the TIMI III Investigators. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q wave infarction enrolled in the TIMI III trial. Am J Cardiol. 1996; 78: 142-147.
• 31 Meade T. The epidemiology of haemostatic and other variables in coronary artery disease. In: Verstraete M, Vermylen J, Lijnen H, Arnout J. eds. Thromb. and Haemostasis 1987. Leuven: International Society on Thrombosis and Haemostasis and Leuven University Press; 1987: 37-59.
• 32 Kannel W, D’Agostino R, Belanger A. Update on fibrinogen as a cardiovascular risk factor. Ann. Epidemiol. 1992; 2: 457-466.
• 33 Tracy R, Arnold A, Ettinger W, Fried L, Meilahn E, Savage P. for the CHS Investigators. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease in the elderly: results from the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol.. In press 1999
• 34 Tracy R, Bovill E, Yanez D, Psaty B, Fried L, Heiss G, Lee M, Polak J, Savage P. for the CHS Investigators. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly: results from the Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 1995; 15: 1269-1279.
• 35 Yarnell J, Baker I, Sweetnam P, Bainton D, O’Brien J, Whitehead P, Elwood P. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991; 83: 836-844.
• 36 Cushman M, Lemaitre R, Kuller L, Psaty B, Macy E, Sharrett A, Tracy R. Fibrinolytic Activation Markers Predict Myocardial Infarction in the Elderly: The Cardiovascular Health Study. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 493-498.
• 37 Cushman M, Psaty B, Macy E, Bovill E, Cornell E, Kuller L, Tracy R. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 1996; 16: 1163-1169.
• 38 Tracy RP, Kleiman NS, Thompson B, Cannon CP, Bovill EG, Brown RG, Collen D, Mahan E, Mann KG, Rogers WJ, Sopko G, Stump DC, Williams DO, Zaret BL. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. Am Heart J. 1998; 135: 29-37.
• 39 de Maat MP, Kastelein JJ, Jukema JW, Zwinderman AH, Jansen H, Groenemeier B, Bruschke AV, Kluft C. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol. 1998; 18: 265-71.
• 40 Zito F, Di Castelnuovo A, Amore C, D’Orazio A, Donati MB, Iacoviello L. Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels. A case-control study in a sample of GISSI-2 patients. Arterioscler Thromb Vasc Biol. 1997; 17: 3489-94.
• 41 Carter AM, Mansfield MW, Stickland MH, Grant PJ. Beta-fibrinogen gene-455 G/A polymorphism and fibrinogen levels. Risk factors for coronary artery disease in subjects with NIDDM. Diabetes Care. 1996; 19: 1265-8.
• 42 Scarabin PY, Bara L, Ricard S, Poirier O, Cambou JP, Arveiler D, Luc G, Evans AE, Samama MM, Cambien F. Genetic variation at the beta-fibrinogen locus in relation to plasma fibrinogen concentrations and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb. 1993; 13: 886-91.
• 43 Fowkes FG, Connor JM, Smith FB, Wood J, Donnan PT, Lowe GD. Fibrinogen genotype and risk of peripheral atherosclerosis. Lancet 1992; 339: 693-6.
• 44 Haverkate F, Thompson S, Pyke S, Gallimore J, Pepys M. Production of c-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
• 45 Haverkate F. Low-grade acute-phase reactions in arteriosclerosis and the consequences for haemostasis. Fibrinolysis 1992; 6 (Suppl. 03) 17-18.
• 46 Liuzzo G, Biasucci L, Gallimore J, Grillo R, Rebuzzi A, Pepys M, Maseri A. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 1994; 331: 417-424.
• 47 Kuller L, Tracy R, Shaten J, Meilahn E. for the MRFIT Research Group. Relationship of C-Reactive Protein and Coronary Heart Disease in the MRFIT nested case-control study. Am. J. Epidemiol. 1996; 144: 537-547.
• 48 Tracy R, Kuller L, Psaty B, Cushman M, Meilahn E, Smith N. C-Reactive Protein and incidence of cardiovascular disease in older women: the Rural Health Promotion Project and the Cardiovascular Health Study. Circulation 1996; 93: 622 (Abstract).
• 49 Koenig W, Sund M, Frohlich M, Fischer H-G, Lowel H, Doring A, Hutchinson W, Pepys M. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999; 99: 237-242.
• 50 Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. NEJM 1997; 336: 973-979.
• 51 Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
• 52 Ridker P, Haughie P. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease. J. Investig. Med. 1998; 46: 391-395.
• 53 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
• 54 Ridker P, Glynn R, Hennekens C. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97: 2007-2011.
• 55 Cushman M, Arnold A, Kuller L, Psaty B, Manolio T, Burke G, Polak J, Tracy R. C-reactive protein and risks of myocardial infarction, stroke and death in an elderly cohort. (abstract). Circulation 1999; 98: 1108.
• 56 Tracy R, Lemaitre R, Psaty B, Ives D, Evans R, Cushman M, Meilahn E, Kuller L. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 1121-1127.
• 57 Sakkinen P, Abbott R, Curb J, Rodriguez B, Yano K, Tracy R. C-reactive protein and incident myocardial infarction in Japanese American men. (abstract). Circulation 1999; 99: 1121.
• 58 Curb J, Abbott R, Rodriguez B, Sakkinen P, Yano K, RP T. The relationship of C-reactive protein to the incidence of thromboembolic stroke. (abstract). Circulation 1999; 99: 1108.
• 59 Tracy R, Macy E, Bovill E, Cushman M, Psaty B, Cornell E, Kuller L. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 2167-2176.
• 60 Tracy R. Atherosclerosis, thrombosis and inflammation: a question of linkage. Fibrinolysis and Proteolysis 1997; 11 (Suppl. 01) 137-142.
• 61 Ettinger W, Harris T, Verdery R, Tracy R, Kouba E. Evidence for inflammation as a cause of hypocholesterolemia in older people. JAGS 1995; 43: 264-266.
• 62 Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? [editorial; comment]. Circulation 1998; 97: 2000-2.
• 63 de Maat M, Haverkate F, Kluft C. C-reactive protein: a cardiovascular risk factor. Report on the CRP hot-topic workshop of October 1, 1997. Fibrinolysis & Proteolysis. 1998; 12: 323-327.
• 64 Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-44.
• 65 Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. (letter). Arthrit. Rheum. 1992; 35: 982-984.
• 66 Cermak J, Key N, Bach R, Balla J, Jacob H, Vercellotti G. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993; 82: 513-520.
• 67 Wolbink GJ, Bossink AW, Groeneveld AB, de Groot MC, Thijs LG, Hack CE. Complement activation in patients with sepsis is in part mediated by C- reactive protein. J Infect Dis. 1998; 177: 81-7.
• 68 Zouki C, Beauchamp M, Baron C, Filep JG. Prevention of In vitro neutrophil adhesion to endothelial cells through shedding of L-selectin by C-reactive protein and peptides derived from C-reactive protein. J Clin Invest. 1997; 100: 522-9.
• 69 Ridker P, Stampfer M, Cushman M, Tracy R, Hennekens C. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998; 97: 425-428.
• 70 Harris T, Ferrucci L, Tracy R, Corti C, Wachholder S, Ettinger W, Heimovitz H, Cohen H, Wallce R. Mortality risk associated with elevated interleukin-6 and C-reactive protein in old age. Am. J. Med.. In press 1998
• 71 Stary H, Chandler A, Dinsmore R, Fuster V, Glalov S, Insull W, Rosenfield M, Schwartz C, Wagner W, Wissler R. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation 1995; 92: 1355-1374.
• 72 Schmidt M, Duncan B, Offenbacher S, Lindberg G, Savage P, Azambuja M, Tracy R, Heiss G. for the ARIC investigators. Markers of inflammation predict incident diabetes in adults: the ARIC study. Lancet. In press 1999